VirTra, Inc.

Stocks

Market Closed - Nasdaq 21:00:00 03/11/2026 GMT			5-day change	1st Jan Change
2.740 ^USD	+3.40%		+2.62%	-34.76%

10-06	VirTra Wins Five-Year CBP Contract With Up to $14 Million in Potential Value	CI
08-20	VirTra Wins $1.5 Million US Army Contract for Firearms Training in Tajikistan	MT

Published on 06/24/2026 at 12:01 am BST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Welcome to VirTra, Inc. 2026 Annual Meeting of Stockholders Call. [Operator Instructions] Please note, this conference is being recorded. I would now

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

10-06	VirTra Wins Five-Year CBP Contract With Up to $14 Million in Potential Value	CI
08-20	VirTra Wins $1.5 Million US Army Contract for Firearms Training in Tajikistan	MT
08-20	VirTra, Inc Receives USD 1.5 Million Sole-Source Contract From U.S. Army To Support Firearms Training In Tajikistan	CI
08-13	VirTra, Inc., Q2 2026 Earnings Call, Aug 13, 2026
08-13	VirTra, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-30	VirTra, Inc. Accepts for Inclusion In U.S. Army Marketplace For Three Mission-Critical Capability Areas	CI
06-28	VirTra, Inc.(NasdaqCM:VTSI) dropped from Russell Microcap Growth Benchmark Index	CI
06-24	VirTra, Inc. - Shareholder/Analyst Call
06-10	Virtra Expands Orlando Presence with Purchase of Dual-Building Campus	CI
05-12	VirTra, Inc., Q1 2026 Earnings Call, May 11, 2026
05-11	VirTra, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-26	VirTra, Inc., Q4 2025 Earnings Call, Mar 26, 2026
03-26	VirTra, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-17	VirTra, Inc Announces Board and Committee Changes, Effective February 16, 2026	CI
02-06	Vivos Therapeutics, Inc. Appoints Gregg C. E. Johnson as Independent Director of the Board and Compensation Committee of the Board, Effective February 4, 2026	CI

Duration

Period

Sector